Dr Stephanie Ling

Stephanie Ling is a Senior Research Scientist within the Mass Spectrometry Imaging group in AstraZeneca where she continues to explore her research interests in using high parameter technologies to understand the tumour microenvironment. The Mass Spectrometry Imaging group is a global capability with a suite of technologies to enable label-free analysis of endogenous and exogenous small molecules and is used to map the abundance and distribution of drugs, their metabolites and the endogenous metabolome directly from the surface of tissue sections. Stephanie is leading the implementation of the novel Imaging Mass Cytometry platform and its integration with Mass Spectrometry Imaging to understand the cell types and phenotypes underlying heterogeneity of drug delivery, response and resistance. The power of the approach is exemplified supporting Oncology as part of the Rosetta CRUK Grand Challenge to create a Complete Cartography of Cancer. In her previous role in the High Content Biology group, she used high content immunofluorescence imaging and CRISPR to develop high throughput screens and insight into mechanism of action for genotoxicity and DNA damage response. Before joining AstraZeneca, Stephanie completed her PhD at the Institute of Cancer Research in the labs of Claus Jorgensen and Chris Marshall, using Mass Spectrometry Proteomics and High Content Imaging to study Tumour-Stroma signalling in Pancreatic Ductal Adenocarcinoma